- Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
- The Jacquet plant in Saint-Beauzire (Limagrain group) is committed to reducing its water consumption by 15% with the signing of the PURE plan (IN FRENCH).
- Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
